XML 23 R25.htm IDEA: XBRL DOCUMENT v2.4.0.6
FAIR VALUE MEASUREMENTS AND DERIVATIVES (Tables)
3 Months Ended
May 04, 2013
FAIR VALUE MEASUREMENTS AND DERIVATIVES  
Schedule of assets and liabilities measured at fair value on recurring basis

 

 

(dollar amounts in thousands)

 

Fair Value at

 

Fair Value Measurements Using Inputs Considered as

 

Description

 

May 4, 2013

 

Level 1

 

Level 2

 

Level 3

 

Assets:

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

56,116

 

$

56,116

 

$

 

$

 

Collateral investments (1)

 

19,929

 

19,929

 

 

 

Deferred compensation assets (1)

 

3,974

 

 

3,974

 

 

Liabilities:

 

 

 

 

 

 

 

 

 

Other liabilities

 

 

 

 

 

 

 

 

 

Derivative liability (2)

 

1,388

 

 

1,388

 

 

 

(dollar amounts in thousands)

 

Fair Value at

 

Fair Value Measurements Using Inputs Considered as

 

Description

 

February 2, 2013

 

Level 1

 

Level 2

 

Level 3

 

Assets:

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

59,186

 

$

59,186

 

$

 

$

 

Collateral investments (1)

 

20,929

 

20,929

 

 

 

Deferred compensation assets (1)  

 

3,834

 

 

3,834

 

 

Liabilities:

 

 

 

 

 

 

 

 

 

Other liabilities

 

 

 

 

 

 

 

 

 

Derivative liability (2)

 

1,567

 

 

1,567

 

 

 

(1) Included in other long-term assets.

(2) Included in other long-term liabilities.

Schedule of impact of fair value accounting for the Company's derivative liability on its consolidated financial statements

 

 

(dollar amounts in thousands)

 

Amount of Gain in
Other Comprehensive
Income
(Effective Portion)

 

Earnings Statement
Classification

 

Amount of Loss
Recognized in Earnings
(Effective Portion) 
(a)

 

Thirteen weeks ended May 4, 2013

 

$

113

 

Interest expense

 

$

(146

)

Thirteen weeks ended April 28, 2012

 

$

1,007

 

Interest expense

 

$

(1,654

)

 

(a) Represents the effective portion of the loss reclassified from accumulated other comprehensive loss.